BridgeBio Oncology Therapeutics Ownership | Who Owns BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics Ownership Summary

BridgeBio Oncology Therapeutics is owned by 184.41% institutional investors, 27.20% insiders. Cormorant asset management, lp is the largest institutional shareholder, holding 57.40% of BBOT shares. BGF World Healthscience A2 is the top mutual fund, with 1.93% of its assets in BridgeBio Oncology Therapeutics shares.

BBOT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	BridgeBio Oncology Therapeutics	184.41%	27.20%	-111.61%
Sector	Healthcare Stocks	50.50%	12.33%	37.17%
Industry	Biotech Stocks	49.09%	12.06%	38.85%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Cormorant asset management, lp	17.88M	57.40%	$160.01M
Deerfield management company, l.p. (series c)	4.89M	15.69%	$43.72M
Omega fund management	3.29M	10.56%	$29.44M
Ecor1 capital	2.82M	9.06%	$25.27M
Alphabet	2.82M	9.06%	$25.27M
Wellington management group llp	2.82M	9.05%	$25.22M
Enavate sciences gp	2.63M	8.43%	$23.51M
Citadel advisors	2.53M	8.12%	$22.63M
Novo	2.19M	7.02%	$19.56M
Blackrock funding, inc. /de	2.09M	6.71%	$18.69M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Omega fund management	3.29M	18.05%	$29.44M
Cormorant asset management, lp	17.88M	8.04%	$160.01M
Enavate sciences gp	2.63M	6.69%	$23.51M
Aisling capital management lp	1.02M	1.91%	$9.11M
Novo	2.19M	1.59%	$19.56M
Ecor1 capital	2.82M	1.07%	$25.27M
Laurion capital management lp	1.92M	0.75%	$17.21M
Alphabet	2.82M	0.63%	$25.27M
Deerfield management company, l.p. (series c)	4.89M	0.52%	$43.72M
Armistice capital	1.33M	0.21%	$11.89M

Top Buyers

Holder	Shares	% Assets	Change
Royce & associates lp	636.52K	0.06%	636.52K
Laurion capital management lp	1.92M	0.75%	457.72K
Aisling capital management lp	1.02M	1.91%	453.39K
Armistice capital	1.33M	0.21%	328.00K
Ensign peak advisors	320.87K	0.01%	320.87K

Top Sellers

Holder	Shares	% Assets	Change
Adage capital partners gp	400.00K	0.01%	-1.00M
Paradigm biocapital advisors lp	-	-	-868.21K
Octagon capital advisors lp	-	-	-719.00K
Eventide asset management	-	-	-541.18K
Silverarc capital management	-	-	-457.41K

New Positions

Holder	Shares	% Assets	Change	Value
Royce & associates lp	636.52K	0.06%	636.52K	$5.70M
Ensign peak advisors	320.87K	0.01%	320.87K	$2.87M
Vanguard fiduciary trust	254.33K	0.00%	254.33K	$2.28M
Schroder investment management group	249.16K	0.00%	249.16K	$2.16M
Granahan investment management	231.04K	0.10%	231.04K	$2.07M

Sold Out

Holder	Change
Fny investment advisers	-100.00
Royal bank of canada	-154.00
Accent capital management	-335.00
China universal asset management	-5.00K
Bellevue group	-6.98K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	67	26.42%	57,435,188	-1.50%	184	0.30%	43	59.26%	11	-8.33%
Dec 31, 2025	10	-75.61%	4,364,186	-92.32%	18	0.03%	8	-80.49%	1	-
Sep 30, 2025	40	-	56,812,263	-	241	-	40	-	-	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
BGF World Healthscience A2	1.55M	1.93%	-
Vanguard Morn Total Stk Mkt Idx Investor	1.42M	1.78%	1.42M
Vanguard Total Stock Mkt Idx Inv	1.42M	1.78%	1.42M
State Street® SPDR® S&P® Biotech ETF	800.67K	1.00%	1.84K
BlackRock Health Sciences Opps Inv A	673.77K	0.84%	-
Vanguard Institutional Extnd Mkt Idx Tr	549.13K	0.69%	5.90K
iShares Biotechnology ETF	315.30K	0.39%	-960.00
BlackRock Health Sciences Term Trust	263.67K	0.33%	-
Fidelity Extended Market Index	245.68K	0.31%	-5.22K
Fidelity Select Biotechnology	240.30K	0.30%	-

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	-
2026 Q1	-	-
2025 Q4	-	-
2025 Q3	-	-

BBOT Ownership FAQ

Who Owns BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics shareholders are primarily institutional investors at 184.41%, followed by 27.20% insiders and -111.61% retail investors. The average institutional ownership in BridgeBio Oncology Therapeutics's industry, Biotech Stocks , is 49.09%, which BridgeBio Oncology Therapeutics exceeds.

Who owns the most shares of BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics’s largest shareholders are Cormorant asset management, lp (17.88M shares, 57.40%), Deerfield management company, l.p. (series c) (4.89M shares, 15.69%), and Omega fund management (3.29M shares, 10.56%). Together, they hold 83.65% of BridgeBio Oncology Therapeutics’s total shares outstanding.

Does Blackrock own BridgeBio Oncology Therapeutics?

BlackRock is not among the top 10 institutional shareholders of BridgeBio Oncology Therapeutics.

Who is BridgeBio Oncology Therapeutics’s biggest shareholder by percentage of total assets invested?

Omega fund management is BridgeBio Oncology Therapeutics’s biggest shareholder by percentage of total assets invested, with 18.05% of its assets in 3.29M BridgeBio Oncology Therapeutics shares, valued at 29.44M$.

Who is the top mutual fund holder of BridgeBio Oncology Therapeutics shares?

BGF World Healthscience A2 is the top mutual fund holder of BridgeBio Oncology Therapeutics shares, with 1.93% of its total shares outstanding invested in 1.55M BridgeBio Oncology Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools